Lv4
488 积分 2023-08-11 加入
Echinococcus multilocularis protoscoleces enhance glycolysis to promote M2 Macrophages through PI3K/Akt/mTOR Signaling Pathway
9天前
已完结
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
7个月前
已完结
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
9个月前
已完结
Evaluating the Benefits and Risks of Ex Vivo Liver Resection and Autotransplantation in Treating Hepatic End-stage Alveolar Echinococcosis
10个月前
已完结
Survival Benefit of Hepatectomy after Complete or Partial Response to Conversion Therapy in Unresectable Hepatocellular Carcinoma (GUIDANCE003): A Multicenter Study
1年前
已完结
Predictive factors and survival outcome of conversion therapy for unresectable hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: Comparative analysis of conversion, partial response and complete response patients
1年前
已完结
HAIC plus lenvatinib and tislelizumab for advanced hepatocellular carcinoma with Vp4 portal vein invasion
1年前
已完结
International journal of surgery 2025 STROCSS 模板
1年前
已完结
The STROCSS 2024 guideline: strengthening the reporting of cohort, cross-sectional, and case-control studies in surgery
1年前
已关闭
Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages
1年前
已完结
皖公网安备34019202002308
